SCHEMBL5226607

SCHEMBL5226607

COc1ccc(OC(C)C#N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA7 P43166 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ CA12 O43570 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48
▸ ALDH1A1 P00352 9/20 0.46
▸ GAA P10253 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ APEX1 P27695 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ TAS1R3 Q7RTX0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9921642 0.83 ALDH1A1 (0.41) CA1CA2CA9ALDH1A1KDM4E
SCHEMBL10906948 0.81 ESR2 (0.46) CA2CA9CA12CA14ALDH1A1
SCHEMBL10572263 0.81 ALDH1A1 (0.43) ALDH1A1GAACYP1A2CYP3A4MAPT
SCHEMBL9918362 0.81 ALDH1A1 (0.37) ALDH1A1GAAMAPTHPGDRAB9A
SCHEMBL15652387 0.81 TDP1 (0.43) ALDH1A1GAAKDM4ECYP3A4MAPT
SCHEMBL6574277 0.81 GAA (0.44) CA1CA2CA9CA12CA14
SCHEMBL11156880 0.81 L3MBTL1 (0.45) ALDH1A1GAAKDM4ECYP1A2NPSR1
SCHEMBL4306370 0.80 KDM4E (0.39) ALDH1A1GAAKDM4ECYP1A2TSHR
SCHEMBL10746306 0.79 CA12 (0.53) CA1CA2CA7CA9CA12
SCHEMBL609371 0.78 CA1 (0.48) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998471-B1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2007-03-14 — — EP disclosed
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 — — US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 — — US disclosed
EP-0998471-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 2000-05-10 — — EP disclosed
WO-1998052935-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 1998-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 CA1 1773/4885CA2 1662/4885CA7 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback